Ann: Biotech Showcase 2022 Presentation, page-31

I estimate US$25-35M in stem cells were made for the GVHD roll out - that's cost to MSB. They are now more than half way through their shelf life.

This made me laugh: "GVHD is a very small indication."

Versus what? The other ones? The other ones that are much larger and further away, those other ones?

You're acting as if these are every day occurrences - they aren't.




Of course to high-roller shareholders like you, these costs are arbitrary.

Throw in the costs of sales staff, and, and, and and we are close to about half of one of the many MSB CRs.

It's a monumental screw up. Cost Fred his job. How SI is still sucking oxygen is beyond me.